A new era in secondary prevention after acute coronary syndrome

New England Journal of Medicine

Volumn 366, Issue 1, 2012, Pages 85-87

  Roe, Matthew T ^a   Ohman, E Magnus ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; PLACEBO; PRASUGREL; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; WARFARIN; XIMELAGATRAN; BLOOD CLOTTING FACTOR 10A; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); DEATH; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LIVER TOXICITY; MEDICAL LITERATURE; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; FACTOR XA; FEMALE; HUMANS; MALE; MORPHOLINES; THIOPHENES;

EID: 84855723464     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1112770     Document Type: Editorial

References (10)

1. Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol 2010;56:254-63.
2. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. (Pubitemid 350106708)
3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
4. Alexander JH, Lopes RD, James S, et al. Apixaban with anti-platelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
5. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
6. Pocock SJ, Mehran R, Clayton TC, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2010;121:43-51.
7. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
8. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97. (Pubitemid 37093920)
9. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011;62:41-57.
10. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011 May 7 (Epub ahead of print).